His main research concerns Internal medicine, Immunology, Chemotherapy, Surgery and Oncology. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Acquired immunodeficiency syndrome. Within one scientific family, he focuses on topics pertaining to Sarcoma under Acquired immunodeficiency syndrome, and may sometimes address concerns connected to Kaposi's sarcoma, Disease, Viral load, Immune reconstitution inflammatory syndrome and Hazard ratio.
The study incorporates disciplines such as Regimen, AIDS-related lymphoma and Cohort in addition to Immunology. His work deals with themes such as Pregnancy, Radiation therapy and Toxicity, which intersect with Chemotherapy. The various areas that Mark Bower examines in his Oncology study include Opportunistic infection, Germinoma and Sepsis.
His primary scientific interests are in Internal medicine, Immunology, Oncology, Acquired immunodeficiency syndrome and Chemotherapy. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. His Immunology research incorporates themes from Sarcoma and Virology.
His research in the fields of Lung cancer overlaps with other disciplines such as In patient. Mark Bower interconnects Viral disease, Cohort study and Cohort in the investigation of issues within Acquired immunodeficiency syndrome. As part of his studies on Chemotherapy, Mark Bower frequently links adjacent subjects like Methotrexate.
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Lymphoma and Immunology. His Internal medicine research focuses on Gastroenterology and how it connects with Pathology. His Oncology study which covers Surgery that intersects with Anal cancer.
His biological study spans a wide range of topics, including Prospective cohort study and Viral load. Mark Bower combines subjects such as Chemotherapy and Hazard ratio with his study of Immunology. His studies in Chemotherapy integrate themes in fields like Anthracycline and Rituximab.
His scientific interests lie mostly in Internal medicine, Oncology, Cancer, Immunology and Surgery. Internal medicine is represented through his Survival analysis, Chemotherapy, Disease, Stage and Cervical cancer research. His Oncology research incorporates elements of Clinical trial, Lymphoma, Cirrhosis, Hepatocellular carcinoma and Dosing.
The concepts of his Cancer study are interwoven with issues in Adverse effect, Pandemic, Incidence and Anoscopy. His Immunology research includes elements of Routine clinical practice, Antibiotic therapy, Antibiotics and Hazard ratio. Mark Bower has researched Surgery in several fields, including Anal Squamous Cell Carcinoma and Erlotinib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.
Malek Djabali;Licia Selleri;Pauline Parry;Mark Bower.
Nature Genetics (1992)
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito.
Hiv Medicine (2012)
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
Michael Cullen;Neil Steven;Lucinda Billingham;Claire Gaunt.
The New England Journal of Medicine (2005)
Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection
Thomas Powles;David Robinson;Justin Stebbing;Jonathan Shamash.
Journal of Clinical Oncology (2009)
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
M. Bower;E.S. Newlands;L. Holden;D. Short.
Journal of Clinical Oncology (1997)
Phase I Trial of Temozolomide Using an Extended Continuous Oral Schedule
Cathryn S. Brock;Edward S. Newlands;Steven R. Wedge;Mark Bower.
Cancer Research (1998)
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - Results from an international study group
Karim Fizazi;Sergei Tjulandin;Roberto Salvioni;José R. Germà-Lluch.
Journal of Clinical Oncology (2001)
Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma
M. Bower;M. Nelson;A.M. Young;C. Thirlwell.
Journal of Clinical Oncology (2005)
Fifty years of multicentric Castleman's disease
Ashita Waterston;Mark Bower.
Acta Oncologica (2004)
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
David J. Pinato;David J. Pinato;Sarah Howlett;Diego Ottaviani;Heather Urus.
JAMA Oncology (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: